Podoplanin expression in oral leukoplakia: Prognostic value and clinicopathological implications

Oral Diseases

Volumn 18, Issue 7, 2012, Pages 692-699

  Kreppel, M ^a,b   Kreppel, B ^a,b   Drebber, U ^a,b   Wedemayer, I ^a,b   Rothamel, D ^a,b   Zoller J E ^a,b   Scheer, M ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

Author keywords

Leukoplakia; Malignant transformation; Podoplanin; SIN grading

Indexed keywords

PODOPLANIN;

ADULT; ARTICLE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; ORAL BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR BIOPSY;

AGED; ALCOHOL DRINKING; ANALYSIS OF VARIANCE; CELL TRANSFORMATION, NEOPLASTIC; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOPLAKIA, ORAL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SMOKING; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84866275894     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2012.01927.x     Document Type: Article

References (50)

1. Amagasa T, Yamashiro M, Ishikawa H (2006). Oral leukoplakia related to malignant transformation. Oral Sci Int 3: 45-55.
2. Amagasa T, Yamashiro M, Uzawa N (2011). Oral premalignant lesions: from a clinical perspective. Int J Clin Oncol 16: 5-14.
3. Axéll T, Pindborg JJ, Smith CJ, van der Waal I (1997). Oral white lesions with special reference to precancerous and tobacco- related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med 25: 49-54.
4. Bagan J, Jimenez Y, Murillo J et al (2007). Lack of association between proliferative verrucous leukoplakia and human papillomavirus infection. J Oral Maxillofac Surg 64: 924-930.
5. Caldeira PC, Aguiar MC, Mesquita RA, do Carmo MA (2011). Oral leukoplakias with different degrees of dysplasia: comparative study of hMLH1, p53, and AgNOR. J Oral Pathol Med 40: 305-311.
6. Carrard V, Haas A, Rados P et al (2011). Prevalence and risk indicators of oral mucosal lesions in an urban population from South Brazil. Oral Dis 17: 171-179.
7. Cox D (1972). Regression model and life-tables. J R Stat Soc 34: 187-220.
8. Funayama A, Cheng J, Maruyama S et al (2011). Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinoma. Pathobiology 78: 171-180.
9. Holmstrup P, Vedtofte P, Reibel J, Stoltze K (2006). Long-term treatment outcome of oral premalignant lesions. Oral Oncol 42: 461-474.
10. Holmstrup P, Vedhofte P, Reibel J, Stoltze K (2007). Oral premalignant lesions: is a biopsy reliable? J Oral Pathol Med 36: 262-266.
11. Inoue H, Miyazaki Y, Kikuchi K et al (2012). Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity. Tumour Biol 33: 183-194.
12. Kaplan EL, Meier P (1958). Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481.
13. Kawaguchi H, El-Naggar A, Papadimitrakopoulou V et al (2008). Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26: 354-360.
14. Kreppel M, Scheer M, Drebber U, Ritter L, Zöller J (2010). Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic findings. Virchows Arch 456: 473-482.
15. Kreppel M, Drebber U, Wedemeyer I et al (2011). Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. Oral Oncol 47: 873-878.
16. Kujan O, Oliver R, Khattab A, Roberts S, Thakker N, Sloan P (2006). Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. Oral Oncol 42: 987-993.
17. Kujan O, Khattab A, Oliver R, Roberts S, Thakker N, Sloan P (2007). Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: an attempt to understand the sources of variation. Oral Oncol 43: 224-231.
18. Lee J, Dedhar S, Kalliuri R, Thompson E (2006). The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981.
19. Lingen MW, Pinto A, Mendes RA et al (2011). Genetics/epigenetics of oral premalignancy: current status and future research. Oral Dis 17(Suppl 1): 7-22.
20. Lippman S, Heymach J (2007). The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 13: 4035-4041.
21. Lodi G, Franchini R, Bez C et al (2010). Detection of survivin mRNA in healthy oral mucosa, oral leucoplakia and oral cancer. Oral Dis 16: 61-67.
22. Martin-Villar E, Scholl F, Gamallo C et al (2005). Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 113: 899-910.
23. Martin-Villar E, Megias D, Castel S, Yurrita M, Vilaro S, Quintanilla M (2006). Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 119: 4541-4553.
24. Matranga D, Di FO, Paderni C et al (2011). Demographic and behavioural profiles of patients with common oral mucosal lesions by a homogeneity analysis. Oral Dis available from: PM:22221322. doi: 10.1111/1601-0825.2011.01888.x.
25. Napier S, Speight P (2008). Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 37: 1-10.
26. Nasser W, Flechtenmacher C, Holzinger D, Hofele C, Bosch FX (2011). Aberrant expression of p53, p16INK4aand Ki-67 as basic biomarker for malignant progression of oral leukoplakias. J Oral Pathol Med 40: 629-635.
27. Pentenero M, Broccoletti R, Carbone M, Conrotto D, Gandolfo S (2008). The prevalence of oral mucosal lesions in adults from the Turin area. Oral Dis 14: 356-366.
28. Pentenero M, Donadini A, Di Nallo E et al (2011). Field effect in oral precancer as assessed by DNA flow cytometry and array-CGH. J Oral Pathol Med 41: 119-123.
29. Pindborg J, Renstrup G, Poulsen H, Silverman S (1963). Studies in oral leukoplakias. V. Clinical and histologic signs of malignancy. Acta Odontol Scand 21: 407-414.
30. Pindborg J, Jolst O, Renstrup G, Roed-Petersen B (1968). Studies in oral leukoplakia: a preliminary report on the period prevalence of malignant transformation in leukoplakia based on a follow-up study of 248 patients. J Am Dent Assoc 76: 767-771.
31. Pitiyage G, Tilakaratne WM, Tavassoli M, Warnakulasuriya S (2009). Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med 38: 737-752.
32. Reibel J (2003). Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 14: 47-62.
33. Ribeiro A, Salles P, da Silva T, Mesquita R (2010). A review of nonsurgical treatment of oral leukoplakia. Int J Dent 2010: 186018.
34. Saintigny P, El-Naggar A, Papadimitrakopoulou V et al (2010). Np63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res 15: 6284-6291.
35. Schepman K, van der Meij E, Smeele L, van der Waal I (1998). Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol 34: 270-275.
36. Shi P, Liu W, Zhou Z, He Q, Jiang W (2010). Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus. Cancer Epidemiol Biomarkers Prev 19: 844-849.
37. Silverman SJ, Gorsky M, Lozada F (1984). Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 53: 563-568.
38. Sroussi HY, Villines D, Epstein J, Alves MC, Alves ME (2007). Oral lesions in HIV-positive dental patients - one more argument for tobacco smoking cessation. Oral Dis 13: 324-328.
39. Syrjanen S, Lodi G, von Bültzingslöwen I et al (2011). Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis 17(Suppl 1): 58-72.
40. Tabor M, Braakhuis B, van der Waal J et al (2003). Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. J Pathol 199: 354-360.
41. Thiery J (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
42. van der Waal I (2009). Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol 45: 317-323.
43. van der Waal I, Axéll T (2002). Oral leukoplakia: a proposal for uniform reporting. Oral Oncol 38: 521-526.
44. van der Waal I, Schepman KP, van der Meij EH, Smeele LE (1997). Oral leukoplakia: a clinicopathological review. Oral Oncol 33: 291-301.
45. van der Waal I, Schepman K, van der Meij E (2000). A modified classification and staging system for oral leukoplakia. Oral Oncol 36: 264-266.
46. Warnakulasuriya S, Newell W, Johnson W, van der Waal I (2007). Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 36: 575-580.
47. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E (2008). Oral epithelial dysplasia classification systems: predictive value, utility, weakness and scope for improvement. J Oral Pathol Med 37: 127-133.
48. Wicki A, Christofori G (2007). The potential role of podoplanin in tumour invasion. Br J Cancer 96: 1-5.
49. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G (2006). Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9: 261-272.
50. Yuan P, Temam S, El-Naggar A et al (2006). Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 107: 563-569.